CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 102 enrolled
Drug / intervention
Santyl +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02581488
NCT02581488Phase 4Completed

Clinical Outcomes for Diabetic Foot Ulcers Treated With Clostridial Collagenase (SANTYL®) Ointment or With a Comparator Product Containing Silver

Smith & Nephew, Inc.·interventional·Posted Oct 21, 2015·Updated Aug 1, 2018

In Brief

A Phase 4 clinical trial evaluating Santyl and Product containing silver for Diabetic Foot and Foot Ulcer, Diabetic. Completed, enrolled 102 participants across 13 sites in 2 countries.

Detailed Summary

This study is designed to test the hypothesis that daily treatment of diabetic foot ulcers with an enzymatic debriding agent, SANTYL, for up to 6 weeks will result in more rapid decrease in ulcer area than diabetic foot ulcers treated with a topical treatment containing silver. After meeting study criteria, participants will be randomly assigned to apply SANTYL or a topical treatment containing silver to their to foot ulcer for up to 6 weeks. At the end of 6 weeks, participants will be followed for an additional 4 weeks to examine the outcome of the study treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 21, 2015
Enrollment StartOct 1, 2015
Primary CompletionJan 12, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.7 years ago

Interventions

Santylbiological

Product containing silverother

Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer